Gary Richmond - Concepedia

Author

Gary Richmond

Also Known As

B Rashbaum, Edwin DeJesus, G Richmond, G. Richmond, Gary J Richmond, Gary J. Richmond, Gary Richmond, Gary J. Richmond, LaMarca, Anthony, M. Ramgopal

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United States)Broward Health Janssen (Belgium)Research Triangle Park Foundation GlaxoSmithKline (United Kingdom)

About

Gary Richmond is an author at GlaxoSmithKline (United States) specializing in medicine, hiv, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	1.8K
2	Public Health	3	3	485
3	Health Sciences	2	2	136
4	Emergency Medicine	1	1	13
5	Endocrinology	1	1	57

Gary Richmond

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond, New England Journal of Medicine	2020	523
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study Pedro Cahn, Anton Pozniak, Horacio Mingrone, The Lancet Treatment And PreventionWeek 48Antiviral Drug DevelopmentAntiviral TherapyDolutegravir Versus Raltegravir	2013	507
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial David A. Margolis, Juan González‐García, Hans-Jürgen Stellbrink, The Lancet Treatment And PreventionMedicinePhase 2BLong-acting Intramuscular CabotegravirAntiviral Therapy	2017	492
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study Edgar T. Overton, Gary Richmond, Giuliano Rizzardini, The Lancet Phase 3BTreatment And PreventionClinical EpidemiologyAntiviral TherapyPharmacotherapy	2020	342
Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV Julian Falutz, Soraya Allas, K Blot, New England Journal of Medicine	2007	306
Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study Joseph J. Eron, Bonaventura Clotet, J. Durant, The Journal of Infectious Diseases	2012	306
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection Sorana Segal‐Maurer, Edwin DeJesus, Hans‐Jürgen Stellbrink, New England Journal of Medicine	2022	270
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1 Brinda Emu, Jeffrey Fessel, Shannon Schrader, New England Journal of Medicine	2018	220
Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain Deanna Kerrigan, Andrea Mantsios, Miguel Górgolas, PLoS ONE	2018	163
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials Giuliano Rizzardini, Edgar T. Overton, Chloe Orkin, JAIDS Journal of Acquired Immune Deficiency Syndromes	2020	137

Page 1